Development
Emergent BioSolutions Inc.
EBS
$6.22
-$0.02-0.32%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -49.50M | -266.70M | -261.30M | -183.00M | -67.00M |
| Total Depreciation and Amortization | 29.60M | 28.00M | 32.90M | 34.60M | 23.00M |
| Total Amortization of Deferred Charges | 5.70M | 5.70M | 8.90M | 1.00M | 1.00M |
| Total Other Non-Cash Items | -200.00K | 227.80M | 250.30M | 200.00K | -29.40M |
| Change in Net Operating Assets | 46.50M | 65.20M | -145.20M | -36.80M | 165.20M |
| Cash from Operations | 32.10M | 60.00M | -114.40M | -184.00M | 92.80M |
| Capital Expenditure | -11.40M | -12.60M | -12.50M | -15.10M | -23.60M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00 | 0.00 | 270.20M | -- | -- |
| Other Investing Activities | 0.00 | -6.30M | -- | -- | -21.80M |
| Cash from Investing | -11.40M | -18.90M | 257.70M | -15.10M | -45.40M |
| Total Debt Issued | 20.00M | -- | -- | -- | 360.00M |
| Total Debt Repaid | -15.90M | -42.90M | -496.20M | -8.40M | -8.50M |
| Issuance of Common Stock | 700.00K | 0.00 | 9.50M | -- | 2.00M |
| Repurchase of Common Stock | -100.00K | -100.00K | -200.00K | -2.10M | -400.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4.70M | -43.00M | -486.90M | -10.50M | 353.10M |
| Foreign Exchange rate Adjustments | -1.50M | 1.10M | -600.00K | -200.00K | 1.10M |
| Miscellaneous Cash Flow Adjustments | -- | -- | 2.60M | -2.60M | -- |
| Net Change in Cash | 23.90M | -800.00K | -341.60M | -212.40M | 401.60M |